CRISPR

CRISPR2-etsrp

ID
ZDB-CRISPR-200423-3
Name
CRISPR2-etsrp
Previous Names
None
Target
Sequence
5' - GGGAAAGGCCCAAGTCACAG - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
The PAM site was "AGG" at the 3' end.
Genome Resources
None
Target Location
Constructs
Genomic Features
Genomic Feature Affected Genomic Regions
ci32Gt etsrp
ci33 etsrp
ci48Gt etsrp
Expression
Gene expression in Wild Types + CRISPR2-etsrp
No data available
Phenotype
Phenotype resulting from CRISPR2-etsrp
No data available
Phenotype of all Fish created by or utilizing CRISPR2-etsrp
Phenotype Fish Conditions Figures
common cardinal vein etsrp expression decreased amount, abnormal etsrpci32Gt/+; nkuasgfp1aTg standard conditions Fig. 7 with image from Chestnut et al., 2019
intersegmental vessel EGFP expression decreased amount, abnormal etsrpci32Gt/+; nkuasgfp1aTg standard conditions Fig. 3 with image from Chestnut et al., 2020
intermediate cell mass of mesoderm etsrp expression decreased amount, abnormal etsrpci32Gt/+; nkuasgfp1aTg standard conditions Fig. 7 with image from Chestnut et al., 2019
anterior lateral plate mesoderm etsrp expression decreased amount, abnormal etsrpci32Gt/+; nkuasgfp1aTg standard conditions Fig. 7 with image from Chestnut et al., 2019
dorsal aorta etsrp expression decreased amount, abnormal etsrpci32Gt/+; nkuasgfp1aTg standard conditions Fig. 7 with image from Chestnut et al., 2019
skeletal muscle cell EGFP expression increased amount, abnormal etsrpci32Gt/+; nkuasgfp1aTg standard conditions Fig. 3 with image from Chestnut et al., 2020
cranial vasculature etsrp expression decreased amount, abnormal etsrpci32Gt/+; nkuasgfp1aTg standard conditions Fig. 7 with image from Chestnut et al., 2019
skeletal muscle cell differentiation increased occurrence, abnormal etsrpci32Gt/+; nkuasgfp1aTg + MO1-etsrp + MO2-etsrp standard conditions Fig. 3 with image from Chestnut et al., 2020
skeletal muscle cell differentiation decreased occurrence, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg chemical treatment by environment: SU5402 Fig. 6 with image from Chestnut et al., 2020
intermediate cell mass of mesoderm etsrp expression decreased distribution, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 7 with image from Chestnut et al., 2019
intersegmental vessel absent, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 8 with image from Chestnut et al., 2019
blood vessel endothelial cell differentiation decreased occurrence, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 3 with imageFig. 4 with imageFig. 5 with image from Chestnut et al., 2020
anterior lateral plate mesoderm etsrp expression absent, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 7 with image from Chestnut et al., 2019
skeletal muscle cell EGFP expression increased amount, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 3 with image from Chestnut et al., 2020
intersegmental vessel decreased amount, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 8 with image from Chestnut et al., 2019
common cardinal vein EGFP expression absent, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 8 with image from Chestnut et al., 2019
common cardinal vein etsrp expression absent, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 7 with image from Chestnut et al., 2019
intersegmental vessel EGFP expression decreased distribution, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 8 with image from Chestnut et al., 2019
cranial vasculature EGFP expression decreased amount, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 8 with image from Chestnut et al., 2019
skeletal muscle cell differentiation increased occurrence, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 3 with imageFig. 4 with imageFig. 5 with image from Chestnut et al., 2020
intersegmental vessel EGFP expression absent, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 8 with image from Chestnut et al., 2019
cranial vasculature EGFP expression decreased distribution, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 8 with image from Chestnut et al., 2019
blood vessel development disrupted, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 8 with imageFig. 9 with image from Chestnut et al., 2019
dorsal aorta etsrp expression absent, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 7 with image from Chestnut et al., 2019
cranial vasculature etsrp expression decreased distribution, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 7 with image from Chestnut et al., 2019
lateral plate mesoderm apoptotic process increased occurrence, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 4 with imageFig. 5 with image from Chestnut et al., 2020
intermediate cell mass of mesoderm etsrp expression decreased amount, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 7 with image from Chestnut et al., 2019
cranial vasculature etsrp expression decreased amount, abnormal etsrpci32Gt/ci32Gt; nkuasgfp1aTg standard conditions Fig. 7 with image from Chestnut et al., 2019
vascular endothelium normal object quality, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg standard conditions Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression decreased amount, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium damaged, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression spatial pattern, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression decreased amount, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression spatial pattern, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
skeletal muscle cell differentiation decreased occurrence, abnormal etsrpci32Gt/+; nkuasgfp1aTg; w32Tg heat shock Fig. 6 with image from Chestnut et al., 2020
vascular endothelium damaged, abnormal etsrpci32Gt/ci32Gt; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression decreased amount, abnormal etsrpci32Gt/ci32Gt; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression spatial pattern, abnormal etsrpci32Gt/ci32Gt; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression spatial pattern, abnormal etsrpci32Gt/ci32Gt; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression spatial pattern, abnormal etsrpci32Gt/ci32Gt; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg standard conditions Fig. 4 from Metikala et al., 2022
vascular endothelium etsrp expression decreased amount, abnormal etsrpci32Gt/ci32Gt; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression decreased amount, abnormal etsrpci32Gt/ci32Gt; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg standard conditions Fig. 4 from Metikala et al., 2022
vascular endothelium morphogenesis of a branching structure decreased process quality, abnormal etsrpci32Gt/ci32Gt; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg standard conditions Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression spatial pattern, abnormal etsrpci32Gt/ci32Gt; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg standard conditions Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression decreased amount, abnormal etsrpci32Gt/ci32Gt; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium regeneration decreased process quality, abnormal etsrpci32Gt/ci32Gt; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression decreased amount, abnormal etsrpci32Gt/ci32Gt; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg standard conditions Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression spatial pattern, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1 standard conditions Fig. 4 from Metikala et al., 2022
vascular endothelium morphogenesis of a branching structure decreased process quality, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1 standard conditions Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression decreased amount, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1 standard conditions Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression decreased amount, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1 chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium regeneration decreased process quality, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1 chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium damaged, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1 chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression spatial pattern, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1 chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression decreased amount, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1 chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression spatial pattern, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1 chemical treatment by environment: metronidazole Fig. 4 from Metikala et al., 2022
vascular endothelium EGFP expression spatial pattern, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1 standard conditions Fig. 4 from Metikala et al., 2022
vascular endothelium mCherry expression decreased amount, abnormal etsrpci32Gt/+; c264Tg/c264Tg; nkuasgfp1aTg/nkuasgfp1aTg + MO4-tal1 standard conditions Fig. 4 from Metikala et al., 2022
skeletal muscle cell differentiation decreased occurrence, abnormal etsrpci32Gt/+; c264Tg; pd1Tg heat shock Fig. 6 with image from Chestnut et al., 2020
Citations